Autres langues ORIC Pharmaceuticals, Inc.

Actions

ORIC

US68622P1093

Temps réel estimé Cboe BZX Autres places de cotation 19:25:58 29/04/2024			Varia. 5j.	Varia. 1 janv.
8,435 ^USD	+4,52 %		-2,58 %	-7,66 %

15/04	ORIC Pharmaceuticals annonce les premiers patients traités dans les trois cohortes d'expansion de l'essai de phase 1b d'ORIC-114 chez des patients atteints de cancer du poumon non à petites cellules (NSCLC) muté	CI
08/04	ORIC Pharmaceuticals, Inc. présente des données précliniques sur deux programmes lors de la réunion annuelle 2024 de l'American Association for Cancer Research (AACR)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	15/04
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	15/04
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	15/04
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting	08/04
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting	08/04
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	08/04
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	05/04
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences	04/04
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index	18/03
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates	11/03
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing	08/03
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference	06/03
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	05/03
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	05/03
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01/03
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01/03
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit	14/02
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ORIC Pharmaceuticals, Inc.

Actions

ORIC

US68622P1093

Autres langues

Filtres